The 340B Program was originally designed to help “uninsured indigent patients gain access to prescription medications.”1 It did so by requiring pharmaceutical manufacturers to extend deeper discounts on average sales price (ASP) to hospitals and clinics serving a high percentage of uninsured, indigent and Medicaid patients. The thinking was that clinics and hospitals would use the savings to stretch their resources … Continue reading “Implications of the New CMS Fee Schedule for 340B Drugs”